Propanc Biopharma Files 8-K: Material Agreement & Equity Sales
Ticker: PPCB · Form: 8-K · Filed: Apr 22, 2024 · CIK: 1517681
| Field | Detail |
|---|---|
| Company | Propanc Biopharma, Inc. (PPCB) |
| Form Type | 8-K |
| Filed Date | Apr 22, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $27,500, $25,000, $0.0017, $0.0014, $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation, equity-sale
TL;DR
Propanc Biopharma inked a deal, took on debt, and sold stock on April 16th.
AI Summary
On April 16, 2024, Propanc Biopharma, Inc. entered into a material definitive agreement. The company also reported the creation of a direct financial obligation and unregistered sales of equity securities. Specific details regarding the agreement, financial obligation, and equity sales were not provided in this initial filing.
Why It Matters
This filing indicates significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing details material definitive agreements, financial obligations, and unregistered equity sales, which can introduce financial and operational risks.
Key Players & Entities
- Propanc Biopharma, Inc. (company) — Registrant
- April 16, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Propanc Biopharma, Inc. on April 16, 2024?
The filing states that Propanc Biopharma, Inc. entered into a material definitive agreement on April 16, 2024, but the specific terms and counterparty are not detailed in this report.
What type of direct financial obligation was created by Propanc Biopharma, Inc.?
The filing indicates the creation of a direct financial obligation by Propanc Biopharma, Inc., but the specific details of this obligation are not provided.
Were there any unregistered sales of equity securities by Propanc Biopharma, Inc.?
Yes, the filing reports unregistered sales of equity securities by Propanc Biopharma, Inc. on or around April 16, 2024.
What is the company's jurisdiction of incorporation and IRS Employer Identification Number?
Propanc Biopharma, Inc. is incorporated in Delaware and its IRS Employer Identification Number is 33-0662986.
What is the business address of Propanc Biopharma, Inc.?
The business address of Propanc Biopharma, Inc. is 302, 6 Butler Street, Camberwell, VIC, 3124, Australia.
Filing Stats: 1,092 words · 4 min read · ~4 pages · Grade level 12.1 · Accepted 2024-04-22 12:12:22
Key Financial Figures
- $27,500 — ny in the aggregate principal amount of $27,500 (the "Note"), for a purchase price of $
- $25,000 — 0 (the "Note"), for a purchase price of $25,000. The Company intends to use the net pro
- $0.0017 — tock at a price ("Conversion Price") of $0.0017 per share (the "Fixed Price"). Provided
- $0.0014 — the Company's Common Stock trades below $0.0014 per share for more than five (5) consec
- $0.001 — then the Fixed Price shall be equal to $0.001 per share. In the Event of Default (as
Filing Documents
- form8-k.htm (8-K) — 43KB
- ex4-1.htm (EX-4.1) — 69KB
- ex10-1.htm (EX-10.1) — 81KB
- 0001493152-24-015494.txt ( ) — 389KB
- ppcb-20240416.xsd (EX-101.SCH) — 3KB
- ppcb-20240416_lab.xml (EX-101.LAB) — 33KB
- ppcb-20240416_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 22, 2024 PROPANC BIOPHARMA, INC. By: /s/ James Nathanielsz Name: James Nathanielsz Title: Chief Executive Officer and Chief Financial Officer